{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:49:13Z","timestamp":1786546153582,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:28:42Z","timestamp":1783078122000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study"],"prefix":"10.1016","volume":"182","author":[{"given":"R.","family":"Demeret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vieles Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Treiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Acket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Fabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Levade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.neurol.2026.05.005_bib0110","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.005_bib0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","article-title":"Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol Ther"},{"issue":"15","key":"10.1016\/j.neurol.2026.05.005_bib0120","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"10063","key":"10.1016\/j.neurol.2026.05.005_bib0125","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neurol.2026.05.005_bib0130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurol.2026.05.005_bib0135","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.005_bib0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.005_bib0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.neurol.2026.05.005_bib0150","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/mus.28372","article-title":"Serious neurologic adverse events in tofersen clinical trials for amyotrophic lateral sclerosis. Fanning L","volume":"71","author":"Lovett","year":"2025","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.005_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s42466-023-00305-0","article-title":"Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases","volume":"6","author":"Vidovic","year":"2024","journal-title":"Neurol Res Pract"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.005_bib0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000518005","article-title":"Cytochemical characterization of cerebrospinal fluid macrophage inclusions in pediatric patients receiving intrathecal nusinersen (SPINRAZA) for spinal muscular atrophy","volume":"66","author":"Schafernak","year":"2022","journal-title":"Acta Cytol"},{"issue":"3","key":"10.1016\/j.neurol.2026.05.005_bib0165","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/ijlh.13392","article-title":"Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen","volume":"43","author":"Machacek","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.neurol.2026.05.005_bib0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fneur.2019.00735","article-title":"Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen","volume":"10","author":"Gingele","year":"2019","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.005_bib0175","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1002\/mus.27763","article-title":"Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen","volume":"67","author":"Sparasci","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2026.05.005_bib0180","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2026.05.005_bib0185","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00415-025-12984-7","article-title":"responses in adult patients with spinal muscular atrophy type 2 or 3 on treatment with nusinersen","volume":"272","author":"Cebulla","year":"2025","journal-title":"J Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2026.05.005_bib0190","doi-asserted-by":"crossref","first-page":"fcab157","DOI":"10.1093\/braincomms\/fcab157","article-title":"Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation","volume":"3","author":"Rolfes","year":"2021","journal-title":"Brain Comm"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.005_bib0195","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12883-023-03255-x","article-title":"Role of the immune system in amyotrophic lateral sclerosis. Analysis of the natural killer cells and other circulating lymphocytes in a cohort of ALS patients","volume":"23","author":"Piccoli","year":"2023","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2026.05.005_bib0200","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00415-009-5097-3","article-title":"Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes","volume":"256","author":"Naor","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.05.005_bib0205","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s10072-024-07301-5","article-title":"Chitinases as a potential diagnostic and prognostic biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"45","author":"Xu","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2026.05.005_bib0210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13023-021-01961-8","article-title":"Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy","volume":"16","author":"Freigang","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:52:34Z","timestamp":1786542754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0035378726005564"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}